Nucleotide excision repair in chronic neurodegenerative diseases

DNA Repair

Volumn 12, Issue 8, 2013, Pages 568-577

  Sepe, Sara ^a   Payan Gomez, Cesar ^a,c   Milanese, Chiara ^a,b   Hoeijmakers, Jan H ^a   Mastroberardino, Pier G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RiMED Foundation   (Italy)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Alzheimer's disease; DNA damage; Huntington's disease; Neurodegeneration; Parkinson's disease; Transcriptomics

Indexed keywords

AGING; ALZHEIMER DISEASE; ANATOMICAL VARIATION; ARTICLE; CHRONIC DISEASE; DEGENERATIVE DISEASE; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

ALZHEIMER'S DISEASE; DNA DAMAGE; HUNTINGTON'S DISEASE; NEURODEGENERATION; PARKINSON'S DISEASE; TRANSCRIPTOMICS;

AGING; ANIMALS; BRAIN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPAIR; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84880637848     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2013.04.009     Document Type: Article

References (106)

1. Kraemer K.H., Patronas N.J., Schiffmann R., Brooks B.P., Tamura D., DiGiovanna J.J. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 2007, 145:1388-1396.
2. Niedernhofer L.J., Garinis G.A., Raams A., Lalai A.S., Robinson A.R., Appeldoorn E., Odijk H., Oostendorp R., Ahmad A., van Leeuwen W., Theil A.F., Vermeulen W., van der Horst G.T., Meinecke P., Kleijer W.J., Vijg J., Jaspers N.G., Hoeijmakers J.H. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006, 444:1038-1043.
3. Fousteri M., Mullenders L.H. Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res. 2008, 18:73-84.
4. Shuck S.C., Short E.A., Turchi J.J. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res. 2008, 18:64-72.
5. Sarker A.H., Tsutakawa S.E., Kostek S., Ng C., Shin D.S., Peris M., Campeau E., Tainer J.A., Nogales E., Cooper P.K. Recognition of RNA polymerase II and transcription bubbles by XPG, CSB, and TFIIH: insights for transcription-coupled repair and Cockayne Syndrome. Mol. Cell 2005, 20:187-198.
6. Tsutakawa S.E., Cooper P.K. Transcription-coupled repair of oxidative DNA damage in human cells: mechanisms and consequences. Cold Spring Harb. Symp. Quant. Biol. 2000, 65:201-215.
7. Jeppesen D.K., Bohr V.A., Stevnsner T. DNA repair deficiency in neurodegeneration. Prog. Neurobiol. 2011, 94:166-200.
8. Sugasawa K. UV-induced ubiquitylation of XPC complex, the UV-DDB-ubiquitin ligase complex, and DNA repair. J. Mol. Histol. 2006, 37:189-202.
9. Araki M., Masutani C., Takemura M., Uchida A., Sugasawa K., Kondoh J., Ohkuma Y., Hanaoka F. Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair. J. Biol. Chem. 2001, 276:18665-18672.
10. Bedez F., Linard B., Brochet X., Ripp R., Thompson J.D., Moras D., Lecompte O., Poch O. Functional insights into the core-TFIIH from a comparative survey. Genomics 2013, 101:178-186.
11. Ito S., Kuraoka I., Chymkowitch P., Compe E., Takedachi A., Ishigami C., Coin F., Egly J.M., Tanaka K. XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients. Mol. Cell 2007, 26:231-243.
12. Winkler G.S., Araujo S.J., Fiedler U., Vermeulen W., Coin F., Egly J.M., Hoeijmakers J.H., Wood R.D., Timmers H.T., Weeda G. TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair. J. Biol. Chem. 2000, 275:4258-4266.
13. Missura M., Buterin T., Hindges R., Hubscher U., Kasparkova J., Brabec V., Naegeli H. Double-check probing of DNA bending and unwinding by XPA-RPA: an architectural function in DNA repair. EMBO J. 2001, 20:3554-3564.
14. Patrick S.M., Turchi J.J. Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity. J. Biol. Chem. 2002, 277:16096-16101.
15. Staresincic L., Fagbemi A.F., Enzlin J.H., Gourdin A.M., Wijgers N., Dunand-Sauthier I., Giglia-Mari G., Clarkson S.G., Vermeulen W., Scharer O.D. Coordination of dual incision and repair synthesis in human nucleotide excision repair. EMBO J. 2009, 28:1111-1120.
16. Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K., Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G., Mullenders L.H., Yamashita S., Fousteri M.I., Lehmann A.R. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol. Cell 2010, 37:714-727.
17. Moser J., Kool H., Giakzidis I., Caldecott K., Mullenders L.H., Fousteri M.I. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol. Cell 2007, 27:311-323.
18. Laine J.P., Egly J.M. When transcription and repair meet: a complex system. Trends Genet. 2006, 22:430-436.
19. Niedernhofer L.J. Nucleotide excision repair deficient mouse models and neurological disease. DNA repair 2008, 7:1180-1189.
20. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. (Berl.) 2006, 112:389-404.
21. Braak H., Braak E. Pathoanatomy of Parkinson's disease. J. Neurol. 2000, 247(Suppl. 2):II3-II10.
22. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science (New York, NY) 1985, 230:561-563.
23. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
24. Gleichmann M., Mattson M.P. Neuronal calcium homeostasis and dysregulation. Antioxid. Redox Signal. 2011, 14:1261-1273.
25. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
26. Yamamoto A., Simonsen A. The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. Neurobiol. Dis. 2011, 43:17-28.
27. Li J., Ma X., Yu W., Lou Z., Mu D., Wang Y., Shen B., Qi S. Reperfusion promotes mitochondrial dysfunction following focal cerebral ischemia in rats. PLoS ONE 2012, 7:e46498.
28. Niatsetskaya Z.V., Sosunov S.A., Matsiukevich D., Utkina-Sosunova I.V., Ratner V.I., Starkov A.A., Ten V.S. The oxygen free radicals originating from mitochondrial complex I contribute to oxidative brain injury following hypoxia-ischemia in neonatal mice. J. Neurosci. 2012, 32:3235-3244.
29. Chen H., Kim G.S., Okami N., Narasimhan P., Chan P.H. NADPH oxidase is involved in post-ischemic brain inflammation. Neurobiol. Dis. 2011, 42:341-348.
30. Benilova I., Karran E., De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
31. Cannon J.R., Greenamyre J.T. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci. 2011, 124:225-250.
32. Martinez A., Portero-Otin M., Pamplona R., Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol. 2010, 20:281-297.
33. Pinto M., Pickrell A.M., Moraes C.T. Regional susceptibilities to mitochondrial dysfunctions in the CNS. Biol. Chem. 2012, 393:275-281.
34. Tsunemi T., La Spada A.R. PGC-1alpha at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 2012, 97:142-151.
35. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
36. Guo J.P., Arai T., Miklossy J., McGeer P.L. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1953-1958.
37. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002, 59:398-407.
38. Braak E., Braak H. Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn. Acta Neuropathol. (Berl.) 1997, 93:323-325.
39. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-284.
40. Braak H., Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol. Aging 1997, 18:S85-S88.
41. Gasser T., Hardy J., Mizuno Y. Milestones in PD genetics. Mov. Disord. 2011, 26:1042-1048.
42. Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov. Disord. 2009, 24:2175-2186.
43. Jellinger K.A. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov. Disord. 2012, 27:8-30.
44. Guzman J.N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P.T., Surmeier D.J. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
45. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
46. Mastroberardino P.G., Piacentini M. Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential. J. Intern. Med. 2010, 268:419-431.
47. Folstein S.E. Huntington's disease: a disorder of families, in the John Hopkins series in contemporary medicine and public health 1989, 251. John Hopkins University Press.
48. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (New York, NY) 1997, 277:1990-1993.
49. Mastroberardino P.G., Iannicola C., Nardacci R., Bernassola F., De Laurenzi V., Melino G., Moreno S., Pavone F., Oliverio S., Fesus L., Piacentini M. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 2002, 9:873-880.
50. Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987, 411:162-166.
51. Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov. Disord. 2001, 16:407-423.
52. Weissman L., de Souza-Pinto N.C., Stevnsner T., Bohr V.A. DNA repair, mitochondria, and neurodegeneration. Neuroscience 2007, 145:1318-1329.
53. Mellon I. Transcription-coupled repair: a complex affair. Mutat. Res. 2005, 577:155-161.
54. Nouspikel T. DNA repair in differentiated cells: some new answers to old questions. Neuroscience 2007, 145:1213-1221.
55. Jaarsma D., Van Der Pluijm I., De Waard M., Haasdijk E., Brandt R., Vermeij M., Rijksen Y., Maas A., Van Steeg H., Hoeijmakers J.H., van der Horst G.T. Age-related neuronal degeneration: complementary roles of nucleotide excision repair and transcription-coupled repair in preventing neuropathology. PLoS Genet. 2011, 7:e1002405.
56. Rapin I., Weidenheim K., Lindenbaum Y., Rosenbaum P., Merchant S.N., Krishna S., Dickson D.W. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. J. Child Neurol. 2006, 21:991-1006.
57. Lawrence N.J., Sacco J.J., Brownstein D.G., Gillingwater T.H., Melton D.W. A neurological phenotype in mice with DNA repair gene Ercc1 deficiency. DNA repair 2008, 7:281-291.
58. Weeda G., Donker I., de Wit J., Morreau H., Janssens R., Vissers C.J., Nigg A., van Steeg H., Bootsma D., Hoeijmakers J.H. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr. Biol. 1997, 7:427-439.
59. Borgesius N.Z., de Waard M.C., Van Der Pluijm I., Omrani A., Zondag G.C., van der Horst G.T., Melton D.W., Hoeijmakers J.H., Jaarsma D., Elgersma Y. Accelerated age-related cognitive decline and neurodegeneration, caused by deficient DNA repair. J. Neurosci. 2011, 31:12543-12553.
60. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5161-5166.
61. Burke S.N., Barnes C.A. Neural plasticity in the ageing brain. Nat. Rev. Neurosci. 2006, 7:30-40.
62. Yankner B.A., Lu T., Loerch P. The aging brain. Annu. Rev. Pathol. 2008, 3:41-66.
63. Halliday G.M., Stevens C.H. Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 2011, 26:6-17.
64. Parpura V., Heneka M.T., Montana V., Oliet S.H., Schousboe A., Haydon P.G., Stout R.F., Spray D.C., Reichenbach A., Pannicke T., Pekny M., Pekna M., Zorec R., Verkhratsky A. Glial cells in (patho)physiology. J. Neurochem. 2012, 121:4-27.
65. Aguzzi A., Barres B.A., Bennett M.L. Microglia: scapegoat, saboteur, or something else?. Science 2013, 339:156-161.
66. Fernandez-Fernandez S., Almeida A., Bolanos J.P. Antioxidant and bioenergetic coupling between neurons and astrocytes. Biochem. J. 2012, 443:3-11.
67. Yang S.Z., Zhang Y.F., Zhang L.M., Huang Y.L., Sun F.Y. Immunohistochemical analysis of nucleotide excision repair factors XPA and XPB in adult rat brain. Anat. Rec. 2008, 291:775-780. (Hoboken, NJ: 2007).
68. Yamamoto A., Nakamura Y., Kobayashi N., Iwamoto T., Yoshioka A., Kuniyasu H., Kishimoto T., Mori T. Neurons and astrocytes exhibit lower activities of global genome nucleotide excision repair than do fibroblasts. DNA repair 2007, 6:649-657.
69. Smith S.C., Robinson A.R., Niedernhofer L., Hetman M. Downregulation of cholesterol biosynthesis genes in the forebrain of ERCC1-deficient mice. Neurobiol. Dis. 2012, 45:1136-1144.
70. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
71. Gamba P., Testa G., Sottero B., Gargiulo S., Poli G., Leonarduzzi G. The link between altered cholesterol metabolism and Alzheimer's disease. Ann. N.Y. Acad. Sci. 2012, 1259:54-64.
72. Usui K., Hulleman J.D., Paulsson J.F., Siegel S.J., Powers E.T., Kelly J.W. Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18563-18568.
73. Shepardson N.E., Shankar G.M., Selkoe D.J. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 2011, 68:1239-1244.
74. Valenza M., Cattaneo E. Emerging roles for cholesterol in Huntington's disease. Trends Neurosci. 2011, 34:474-486.
75. de Waard M.C., Van Der Pluijm I., Zuiderveen Borgesius N., Comley L.H., Haasdijk E., Rijksen Y., Ridwan Y., Zondag G., Hoeijmakers J.H., Elgersma Y., Gillingwater T.H., Jaarsma D. Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. Acta Neuropathol. (Berl.) 2010, 120:461-475.
76. Sands A.T., Abuin A., Sanchez A., Conti C.J., Bradley A. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 1995, 377:162-165.
77. Cheo D.L., Ruven H.J., Meira L.B., Hammer R.E., Burns D.K., Tappe N.J., van Zeeland A.A., Mullenders L.H., Friedberg E.C. Characterization of defective nucleotide excision repair in XPC mutant mice. Mutat. Res. 1997, 374:1-9.
78. de Vries A., van Oostrom C.T., Hofhuis F.M., Dortant P.M., Berg R.J., de Gruijl F.R., Wester P.W., van Kreijl C.F., Capel P.J., van Steeg H., Verbeek S.J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 1995, 377:169-173.
79. Bindoff L.A., Birch-Machin M., Cartlidge N.E., Parker W.D., Turnbull D.M. Mitochondrial function in Parkinson's disease. Lancet 1989, 2:49.
80. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
81. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-723.
82. Parker W.D., Mahr N.J., Filley C.M., Parks J.K., Hughes D., Young D.A., Cullum C.M. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 1994, 44:1086-1090.
83. Parker W.D., Parks J., Filley C.M., Kleinschmidt-DeMasters B.K. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994, 44:1090-1096.
84. Horowitz M.P., Milanese C., Di Maio R., Hu X., Montero L.M., Sanders L.H., Tapias V., Sepe S., van Cappellen W.A., Burton E.A., Greenamyre J.T., Mastroberardino P.G. Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid. Redox Signal. 2011, 15:855-871.
85. Mastroberardino P.G., Orr A.L., Hu X., Na H.M., Greenamyre J.T. A FRET-based method to study protein thiol oxidation in histological preparations. Free Radic. Biol. Med. 2008, 45:971-981.
86. Cuervo A.M., Wong E.S., Martinez-Vicente M. Protein degradation, aggregation, and misfolding. Mov. Disord. 2010, 25(Suppl. 1):S49-S54.
87. Magen I., Chesselet M.F. Genetic mouse models of Parkinson's disease. The state of the art. Prog. Brain Res. 2010, 184:53-87.
88. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (New York, NY) 1996, 274:99-102.
89. Ramaswamy S., McBride J.L., Kordower J.H. Animal models of Huntington's disease. ILAR J. 2007, 48:356-373.
90. Wheeler V.C., Auerbach W., White J.K., Srinidhi J., Auerbach A., Ryan A., Duyao M.P., Vrbanac V., Weaver M., Gusella J.F., Joyner A.L., MacDonald M.E. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
91. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 2000, 9:503-513.
92. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 2002, 175:35-48.
93. Miller R.M., Kiser G.L., Kaysser-Kranich T., Casaceli C., Colla E., Lee M.K., Palaniappan C., Federoff H.J. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp. Neurol. 2007, 204:421-432.
94. Hawrylycz M.J., Lein E.S., Guillozet-Bongaarts A.L., Shen E.H., Ng L., Miller J.A., van de Lagemaat L.N., Smith K.A., Ebbert A., Riley Z.L., Abajian C., Beckmann C.F., Bernard A., Bertagnolli D., Boe A.F., Cartagena P.M., Chakravarty M.M., Chapin M., Chong J., Dalley R.A., Daly B.D., Dang C., Datta S., Dee N., Dolbeare T.A., Faber V., Feng D., Fowler D.R., Goldy J., Gregor B.W., Haradon Z., Haynor D.R., Hohmann J.G., Horvath S., Howard R.E., Jeromin A., Jochim J.M., Kinnunen M., Lau C., Lazarz E.T., Lee C., Lemon T.A., Li L., Li Y., Morris J.A., Overly C.C., Parker P.D., Parry S.E., Reding M., Royall J.J., Schulkin J., Sequeira P.A., Slaughterbeck C.R., Smith S.C., Sodt A.J., Sunkin S.M., Swanson B.E., Vawter M.P., Williams D., Wohnoutka P., Zielke H.R., Geschwind D.H., Hof P.R., Smith S.M., Koch C., Grant S.G., Jones A.R. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012, 489:391-399.
95. Ng J.M., Vermeulen W., van der Horst G.T., Bergink S., Sugasawa K., Vrieling H., Hoeijmakers J.H. A novel regulation mechanism of DNA repair by damage-induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein. Genes Dev. 2003, 17:1630-1645.
96. van der Horst G.T., Meira L., Gorgels T.G., De Wit J., Velasco-Miguel S., Richardson J.A., Kamp Y., Vreeswijk M.P., Smit B., Bootsma D., Hoeijmakers J.H., Friedberg E.C. UVB radiation-induced cancer predisposition in Cockayne syndrome group A (Csa) mutant mice. DNA Repair 2002, 1:143-157.
97. van der Horst G.T., van Steeg H., Berg R.J., van Gool A.J., de Wit J., Weeda G., Morreau H., Beems R.B., van Kreijl C.F., de Gruijl F.R., Bootsma D., Hoeijmakers J.H. Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell 1997, 89:425-435.
98. Melquist S., Craig D.W., Huentelman M.J., Crook R., Pearson J.V., Baker M., Zismann V.L., Gass J., Adamson J., Szelinger S., Corneveaux J., Cannon A., Coon K.D., Lincoln S., Adler C., Tuite P., Calne D.B., Bigio E.H., Uitti R.J., Wszolek Z.K., Golbe L.I., Caselli R.J., Graff-Radford N., Litvan I., Farrer M.J., Dickson D.W., Hutton M., Stephan D.A. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am. J. Hum. Genet. 2007, 80:769-778.
99. Sijbers A.M., van der Spek P.J., Odijk H., van den Berg J., van Duin M., Westerveld A., Jaspers N.G., Bootsma D., Hoeijmakers J.H. Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic Acids Res. 1996, 24:3370-3380.
100. Raji N.S., Krishna T.H., Rao K.S. DNA-polymerase alpha, beta, delta and epsilon activities in isolated neuronal and astroglial cell fractions from developing and aging rat cerebral cortex. Int. J. Dev. Neurosci. 2002, 20:491-496.
101. Gao Y., Katyal S., Lee Y., Zhao J., Rehg J.E., Russell H.R., McKinnon P.J. DNA ligase III is critical for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair. Nature 2011, 471:240-244.
102. Chan C.S., Gertler T.S., Surmeier D.J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S63-S70.
103. Lewis M.M., Du G., Kidacki M., Patel N., Shaffer M.L., Mailman R.B., Huang X. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol. Aging 2012.
104. Colpan M.E., Slavin K.V. Subthalamic and red nucleus volumes in patients with Parkinson's disease: do they change with disease progression?. Parkinsonism Relat. Disord. 2010, 16:398-403.
105. Doty R.L. Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 2012, 8:329-339.
106. Grinberg L.T., Rueb U., Alho A.T., Heinsen H. Brainstem pathology and non-motor symptoms in PD. J. Neurol. Sci. 2010, 289:81-88.